Artivion, Inc. reports developments for a cardiac and vascular surgery medical device business focused on aortic disease. Recurring updates cover aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, along with preservation services for cardiac and vascular tissues and product sales across international markets.
Company news also includes quarterly and annual financial results, clinical presentations tied to NEXUS and AMDS aortic-disease programs, FDA and PMA-related regulatory developments, financing and capital-structure actions, investor conference participation, and governance matters. The company’s disclosures often connect revenue trends to stent grafts, On-X, BioGlue, preservation services, and other product categories used by cardiac and vascular surgeons.
Artivion, a leader in cardiac and vascular surgery, announced an Investor & Analyst Day set for March 23, 2022, in New York City. The event, starting at 9:00 AM ET, will feature management presentations and discussions from cardiac and vascular surgeons focusing on aortic disease. Attendees can expect insights into Artivion's product portfolio, market strategies, and financial performance. A live webcast will be available on Artivion’s website, with archived access post-event. Registration for in-person attendance is required by March 18, 2022.
Artivion, Inc. (NYSE: AORT) will participate in the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, with a virtual fireside chat starting at 2:40 p.m. ET. Interested parties can access a live webcast on the company’s website at www.artivion.com. An archived version will be available for 90 days following the event. Headquartered in Atlanta, Georgia, Artivion specializes in solutions for aortic diseases, offering products in over 100 countries.
Artivion reported a record revenue of $79.4 million for Q4 2021, a 16.9% increase from Q4 2020. Full-year revenue reached $298.8 million, marking an 18.0% increase year-over-year. Despite growth, the company faced a net loss of ($20.1 million) in Q4 and ($14.8 million) for 2021. Artivion anticipates a 9.0% to 11.0% revenue growth in 2022, targeting revenues between $319.0 million and $325.0 million. Key developments include FDA approvals and advancements in clinical trials, underscoring the company's commitment to innovation in cardiac and vascular surgery.
Artivion, Inc. (NYSE: AORT) announced that its fourth quarter and full year 2021 financial results will be released on February 17, 2022, after market close. A teleconference and live webcast will occur at 4:30 p.m. ET to discuss these results, hosted by Pat Mackin, the company’s CEO. The financial report is expected to include comprehensive statistics reflecting Artivion's performance over the year. Investors can access the live call and a replay through the company's Investor Relations website.
Artivion (NYSE: AORT) announced the publication of results from the PROACT clinical trial in The Annals of Thoracic Surgery, focusing on the On-X mechanical mitral valve replacement. The trial demonstrated that patients could safely be managed with lower-intensity warfarin and aspirin, enhancing anticoagulation management post-surgery. Presented at the Society of Thoracic Surgeons' Annual Meeting, the findings could influence practice guidelines significantly. Ongoing trials aim to assess the safety of apixaban for patients with On-X aortic valves.